Extended Data Fig. 5: Specificity analysis of CD8 cells in ERT2-CL mice using MHC-I tetramers.
From: Mechanism of EBV inducing anti-tumour immunity and its therapeutic use
a, Representative FACS analysis of splenic CD8 cells from control mice (ERT2-C) or mice expressing inducible LMP1 (ERT2-CL) stained with survivin20–28 tetramer (Surv-Tetrm) versus an irrelevant control tetramer (H-2Db loaded with the LCMV GP33–41 epitope peptide (LCMV GP-Tetrm)). b, Validation of the LCMV GP-tetramer by staining splenic CD8 cells from LCMV (clone 13)-infected mice at day 8 post-infection, versus uninfected control mice. c, Representative FACS analysis of splenic CD8 cells from the indicated mice stained with anti-CD44 and Surv-Tetrm (top) or EPHA2682–689 tetramer (EPHA2-Tetrm) (bottom). d, FACS analysis of splenic CD8 cells from the indicated mice stained with the indicated tetramers labelled with PE and APC. Representative FACS plots are shown on the left, and summary data on the right. Each circle represents one mouse; bars show mean ± s.e.m. All ERT2-CL and littermate control mice were analysed on day 5 after tamoxifen treatment. Mice used in a, c are on the CB6F1 background; in b, d on the B6 background. Statistics and reproducibility are presented in the Supplementary Information.
